Labcorp Holdings Inc. · NYSE:LH
Labcorp — Q4 2025 Earnings Presentation
16 slides from Labcorp's earnings presentation, Feb 17, 2026
Slide 1: Labcorp Q4 2025 Financial Results
diooqp| UOTJCWIOJU] jetoueul, [eyuouroyddn¢s COT JoWeNd YNOJ
Slide 2: Forward-looking statements
diooqn| @) ‘““SNOILVUAdO 4O SLINSIY GNV NOILIGNOD TVIDNVNIJ 4O SISATVNV GNV NOISSNDSIC S.LNINIOVNVA,, Sulpoay ay} sapun ‘O-OT Suu0y Juanbasqns pub ‘y-OT w4o4 uo Joday jonuuy juadas JSOW S,AUDdWOD ay} UI uoljowuoful ay} Bulpnjoul 99S ay} ym sbuijif s,Auodwios ay] fo Mainas 0 YIM UOljIUN{UOD U! Poa aq
Slide 3: Non-GAAP financial measures
‘uoljejuasad siy} SulAuedwozze sajqe} ay} Ul papnjdu! ave UO!}eWOJU! [e!INUeUIJ paysn[pe Uleya. JO} pasn Sway! jelvads,, asiudwod jey} sjUaUOdWOD ay} JO UO!}edIJ]UapP! Ue PUue SaunseawW qYVWO ajqesedwod jsowW ay} 0} saunseaw dVV95-uoU asay} JO SUO!}eIIDUOIaY ‘salUedWOD 4394}0 Aq pajuasaid saunseawW
Slide 4: Adjusted EBITDA and operating income
xXT'Z xXTZ Xt7Z xr'Z X77 XE7 x7 xG°Z XG°Z X67 T'78g$ €0T9S 8'L79$ 9°09S$ vEzSS 9°7LS S'69$ €°89$ 9°69$ v'OLs v96S 0'L6$ 7796S 9'T6$ ZO0TS$ S7zOv S7ZOE SZ0Z SZOT vzov diooqn| @) ‘sluajpainba ysb9 pub Yysb9 ssaj 1qap {010} sjonbaigap1an (Z) “TT apyjs uo uojzpy|2U0084 aas ‘sway! joI2ads pup saB.04> Bul
Slide 5: Diagnostics Laboratories revenue
diosqn| @) Burpunos 0} anp 3o0f30u AoW (T) “VE €62S payoday se ‘sanuanay KIT TZ yoedu adueyoxq us1as04 %9'0 TLLS Aduadin> }Ue}sUOD ‘Sanuandy SadiAsas Asojesoge7] euweydoig %>S 62L'7S payoday se ‘sanuanay %0'0 (T) peduy| a8ueyoxq uslas04 *>S OEL‘7s Aduasin3 yUeysUOD ‘sanuaray 59140}e10ge7 Ssouselq %9
Slide 6: Diagnostics Laboratories full year results
diosqn| @) Burpunos 0} anp 3o0f30u AoW (T) %0'9 860‘ES payoday se ‘sanuanay KO? 8S yoedu adueyoxy us1as04 %0'V OvO‘ES Aduasin3 jue suOD ‘sanuanay SadIAJas Aioje10ge7 eueydoig OL LL8‘0TS payoday se ‘sanuanay (%T'0) (oT) yeduy| asueyoxq u319404 KEL L88‘0TS Aduadin jueysuOD ‘sanuaray 59110} e10ge7 SIso
Slide 7: Revenue by geographic distribution
HG EB vsn %G9T ()PHOM Jo 3s984 uO!}NQIIysIq 214de1s0a5H diooqn| @) anuanay j010} fo %OT uBy} ssaj JOf sjuno290 A2ua4in9 UBiasof 1sa640) ay) ‘sarquauin9 (o1anas ul paziuBo2as sanuanay (T) KVLL RIC saloyesoqey A Sad1Alag soijsouseiq euneudora uo!}NqIAjsSIq JUaWZIS UONNGISIG, SNUdADY SZOZ Jaen?) YWNoA
Slide 8: Biopharma Laboratory Services results
‘ diooqn| @) “unnoy u) pazsajfal aio sjuawiaas60 juawabnuow qo] woufanuanay (¢) uolssan oud wouf pazopdn xi sahog Szoz sD (Z) “pz0z pub Ezoz Uy (6uI]S2} 6T-GIAOD 40f }daaxa suoosado ssaujsng s,AubdusoD ay}) ssauisng asoq ay} J2a/fas xIWV 4aADg PUD XIV I14a}0SZ SA auyNoY —(T) O'E6L T66L 8 ysl eT7l oz
Slide 9: Revenue breakdown by volume and price/mix
diooqn| @) ‘Bulpunod 0} anp ioofjou AoW (S) ‘App Jaunb ysas09u 342 0} papunos aib sazuDUA Aog (Pp) ‘quaouad a2upUDA (suonisinbad UJ) aWIN/OA ssaj ‘{UadIad a2UDIIDA anuaNad sb payDjn2|0D :juaduad XI! / arid (E) auinjon sad sould Aq papialp auinjoa uj aBupyo AOA “Juaddad aouDUUDA (suoIyisinbad ul) aui
Slide 10: Biopharma Laboratory Services backlog
é diooqn| @) uolp/sub4) AQuadn2 uBlasof pub suojjo]}a2uD2 wads }2DdwI ay} apnjau! uMoYs stjnsay —(T) vZ0Z ‘TE Jaquuasagq jo sy S707 ‘TE YJ 40 SY SZ0Z ‘O€ auns jo sy SZOZ ‘O€ Jaquiaidas Jo sy S207 ‘TE Jequiacaq Jo sy SYy}UOW aAjam} IXaU ay} Ul SopyjIeq Woy Soppeg WaAUO) 0} payadxa anuanas payewiysy X
Slide 11: 2026 free cash flow and financial position
OT diooqn| @) ML] fo uonnjsundy Kouasno uBta40f mods joodwut un sapnjrUt aDUPPIND OZOT 10 fo uounjsund Cuasdns UBia40f wo4f Joodult UD SapNjoUL BIUPPIND 9ZOT (@) suonpututja uoyopsups) Kupduoosoju fo jou pajuasaad s1 antiaaad Jaa] astaduaqUst () Fo fo vornpjsuns) KuaLind UBIadof wodf joodul uD sapny
Slide 12: Adjusted EBITDA reconciliation
TT diooqn| @) “sjassb 1a4}0 pub sajqi6upqut fo uonoziuowly pup ‘sjuawutoduy Jasso 4ayjo pud jj¢poog ‘sa6soyo Jayjo pub BuLINyansjsay Bulpnjoxa auioouy Buyosado parsodui! oy) suausnipo ay) fo uooWWNs ay) JUasasday saBsDY> JoI9ads A430 (T) Tv8ss €0T9$ 8L79$ 9°09S$ vEzSS 97L s'69 €°89 9°69 vol v96 O46
Slide 13: Adjusted EPS reconciliation
diooqn| @) sve $ Lov $ OL'T $ 86T $ aueys UOWWOD Jad s8ulUsea painjig TB CEs Tv8 TEs Sulpueysjno saseys paznjip asesane payysiay v'062 $ 6 8EE S vEvT S LYST $ “2U| SBUIPJOH duosge) 0} ajqeynqisj}e sBulusea JN (70) (Z'0) (70) {z°0) S949}! Bul]}O4]UODUOU 34} O} aqeINqijqe sSuIWeA JON :SS97 9067 T6EE Y
Slide 14: Adjusted net income reconciliation
eT LST $ vv or $ vss $ 9v'0T $ vs SEB vrs 88 €0E7'T $ TLLE'T $ O9vZ $ $918 $ (TT) (T) (TT) (2T) vTEe'T vBLe'T ULbL LLL8 LE9E 8°80v viz Eyrad T'S6S'T TLBL'T S656 SLOT (s‘vT) (v's) 709 (o'ss) (pT) (60) (y'T) (€€T) EU est aad est (€'802) (€'€7z) (802) (t'vzz) OL6L'T 9'T00'% £:980'T Lv8e'T = = es ev - -
Slide 15: Adjusted net income per share reconciliation
* — duoogqn) @ “svt § wot $ ve $ Lov S$ aueys sad awoou! Jau paisnipy v8 ses 78 TEs Sulpue}s}no saseys paynjip adesane payysiaM EOECTS CLLET S vo6e $ 68E— S$ @wWoduU! Jeu palsnipy (ETST) (0'6ZT) (LEv) (3°22) (y SJUaWySN{pe yo yoeduI xe} BWOdU| €0 90 - (z'0) Jao (0°08) (8°€) (€9T) - ) UBWAsUNquIIaJ V
Slide 16: Notes on adjusted measures
= diooqn| @) “wai! yoea 0} ajqeaiidde aye, xeq ay uo paseq pajeinoje9 sjuauysnipe Jo edu xey aWOIUI “saadojduia pasa, 0} suo}eSI|qo uleqa0 Jo JUaLA}IJas 03 anp Ue|d UOISUAd ’s'7 Ss}! 0} payejay aBIeYD e paznou! AUedWOD ay), “ssauisng suoinjos sjyauag Aso}esOge] UOIe|g ay} JO UO!USOdsip ay} UO UIeS e